1. Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity
- Author
-
Lando Janssen, Maria T. E. Hopman, Nicole M. A. Blijlevens, Jeroen Janssen, Silvie Timmers, Meggie M.C.M. Drissen, Esmée A. Bakker, Malou A H Nuijten, Hematology, and CCA - Cancer Treatment and quality of life
- Subjects
medicine.medical_specialty ,Side effect ,medicine.drug_class ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,Population ,Physical activity ,Tyrosine-kinase inhibitor ,Article ,Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14] ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Internal medicine ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Medicine ,Life Science ,Humans ,education ,Exercise ,Protein Kinase Inhibitors ,Fatigue ,030304 developmental biology ,Netherlands ,0303 health sciences ,education.field_of_study ,business.industry ,Metabolic Disorders Radboud Institute for Health Sciences [Radboudumc 6] ,Myeloid leukemia ,Hematology ,medicine.disease ,Leukemia ,030220 oncology & carcinogenesis ,Human and Animal Physiology ,Fysiologie van Mens en Dier ,Female ,business ,Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] ,Chronic myelogenous leukemia - Abstract
Contains fulltext : 245055.pdf (Publisher’s version ) (Open Access) Fatigue is a common side effect of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML) patients. However, the prevalence of TKI-induced fatigue remains uncertain and little is known about predictors of fatigue and its relationship with physical activity. In this study, 220 CML patients receiving TKI therapy and 110 gender- and age-matched controls completed an online questionnaire to assess fatigue severity and fatigue predictors (Part 1). In addition, physical activity levels were objectively assessed for 7 consecutive days in 138 severely fatigued and non-fatigued CML patients using an activity monitor (Part 2). We demonstrated that the prevalence of severe fatigue was 55.5% in CML patients and 10.9% in controls (P
- Published
- 2020
- Full Text
- View/download PDF